Form 4: Enanta Pharmaceuticals Director Acquires Stock Options

Director Terry Vance acquires 15,700 stock options in Enanta Pharmaceuticals, exercisable over one year starting March 13, 2025.

Summary

• Terry Vance, a director of Enanta Pharmaceuticals, acquired 15,700 stock options on March 13, 2025.
• The exercise price of these options is $6.83 per share.
• The options become exercisable monthly in substantially equal installments over one year, beginning March 13, 2025.
• The final monthly installment vests on the nearest trading day preceding the 2026 annual meeting of stockholders.
• The options expire on March 13, 2035.
• A power of attorney was filed, authorizing certain individuals to execute forms on behalf of Terry Vance.

Sentiment

Score: 6

Explanation: The document itself is neutral, simply reporting a transaction. The sentiment is slightly positive as it reflects a director's increased stake in the company, suggesting confidence.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the vesting schedule of the options extends into the future.

Industry Context

This is a routine filing related to insider transactions, common in publicly traded companies. It provides transparency into the holdings and transactions of company insiders.

Comparison to Industry Standards

• Stock option grants to directors are a common practice in the pharmaceutical industry, used to align the interests of management with those of shareholders.
• Companies like Gilead Sciences, Vertex Pharmaceuticals, and Biogen also regularly grant stock options to their directors and executives as part of their compensation packages.
• The vesting schedules and exercise prices are typically structured to incentivize long-term value creation.

Key Dates